Research ArticleOsteoarthritis

Targeting cartilage EGFR pathway for osteoarthritis treatment

See allHide authors and affiliations

Science Translational Medicine  13 Jan 2021:
Vol. 13, Issue 576, eabb3946
DOI: 10.1126/scitranslmed.abb3946

You are currently viewing the editor's summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Enhancing EGFR to offset osteoarthritis

Cartilage degeneration in osteoarthritis causes pain and limits mobility. Wei et al. investigated epidermal growth factor receptor (EGFR) signaling as a potential targeted disease-modifying treatment, because EGFR activity is linked to cartilage homeostasis. Cartilage-specific genetic overactivation of EGFR resulted in enlarged cartilage, an expanded tissue progenitor cell population, and resistance to surgically induced osteoarthritis in mice. Treating mice with transforming growth factor–α (an EGFR ligand) conjugated to nanoparticles via intra-articular injections protected against cartilage degeneration and attenuated pain in an osteoarthritis model. Results show how targeting EGFR signaling could potentially treat osteoarthritis.

View Full Text

Stay Connected to Science Translational Medicine